1. Home
  2. MYND vs NEUP Comparison

MYND vs NEUP Comparison

Compare MYND & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mynd.ai Inc.

MYND

Mynd.ai Inc.

N/A

Current Price

$0.38

Market Cap

19.2M

Sector

Real Estate

ML Signal

N/A

Logo Neuphoria Therapeutics Inc.

NEUP

Neuphoria Therapeutics Inc.

N/A

Current Price

$3.73

Market Cap

20.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MYND
NEUP
Founded
1998
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
19.2M
20.6M
IPO Year
2017
2002

Fundamental Metrics

Financial Performance
Metric
MYND
NEUP
Price
$0.38
$3.73
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
43.1K
46.7K
Earning Date
05-27-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$15,649,448.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$3.19
52 Week High
$1.15
$21.31

Technical Indicators

Market Signals
Indicator
MYND
NEUP
Relative Strength Index (RSI) 44.57 43.28
Support Level $0.30 $3.70
Resistance Level $0.44 $4.15
Average True Range (ATR) 0.05 0.11
MACD -0.01 -0.01
Stochastic Oscillator 11.38 8.82

Price Performance

Historical Comparison
MYND
NEUP

About MYND Mynd.ai Inc.

Mynd.ai Inc provides world'wide, end-to-end, learning solutions and collaboration tools to help teachers, schools, students, and professionals realize their greatest potential. The company has single reporting segment. The company has presence in United States and Rest of world. The company generates majority of revenue from United States.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: